Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Tax Provisions (2021 - 2025)

Historic Tax Provisions for Rhythm Pharmaceuticals (RYTM) over the last 4 years, with Q3 2025 value amounting to $111000.0.

  • Rhythm Pharmaceuticals' Tax Provisions rose 13226.74% to $111000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $438000.0, marking a year-over-year decrease of 3282.21%. This contributed to the annual value of $346000.0 for FY2024, which is 3865.25% down from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' Tax Provisions stood at $111000.0, which was up 13226.74% from $337000.0 recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Tax Provisions' 5-year high stood at $22.0 million during Q1 2021, with a 5-year trough of -$9.0 million in Q3 2021.
  • Over the past 4 years, Rhythm Pharmaceuticals' median Tax Provisions value was $153500.0 (recorded in 2023), while the average stood at $787250.0.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Tax Provisions plummeted by 19347.83% in 2024, and later surged by 13226.74% in 2025.
  • Rhythm Pharmaceuticals' Tax Provisions (Quarter) stood at -$9.0 million in 2021, then skyrocketed by 102.18% to $196000.0 in 2023, then plummeted by 145.92% to -$90000.0 in 2024, then skyrocketed by 223.33% to $111000.0 in 2025.
  • Its Tax Provisions was $111000.0 in Q3 2025, compared to $337000.0 in Q2 2025 and $80000.0 in Q1 2025.